Occam Places Phil Tagari as CSO at insitro
insitro, a Casdin/ARCH/GV investment, is a data-driven drug discovery and development company using machine learning and computation at scale to transform the way that drugs are discovered and developed for patients. Since its founding in mid-2018, the San Francisco-based company has raised over $800M from top tech, biotech, and crossover investors.
Philip Tagari was placed as insitro’s CSO in late 2022. Tagari joined insitro following a 24-year career at Amgen, where he led the organization's research platforms for over a decade as Vice President, Research - Therapeutic Discovery.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.